600867.SS
Latest Trade
17.35CNYChange
0.05(+0.29%)Volume
9,168,623Today's Range
-
17.4452 Week Range
-
20.11As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 17.30 |
|---|---|
Open | 17.36 |
Volume | 9,168,623 |
3M AVG Volume | 422.85 |
Today's High | 17.44 |
Today's Low | 17.07 |
52 Week High | 20.11 |
52 Week Low | 10.94 |
Shares Out (MIL) | 2,033.99 |
Market Cap (MIL) | 35,188.00 |
Forward P/E | 35.74 |
Dividend (Yield %) | 1.16 |
Tonghua Dongbao Pharmaceutical's 2018 Net Profit Up 0.25 Percent Y/Y
Tonghua Dongbao Pharmaceutical's Board Elects Leng Chunsheng As New Chairman
Tonghua Dongbao Pharma's Shareholder To Increase Shareholdings In The Company By 200-300 Mln Yuan
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.
Industry
Biotechnology & Drugs
Executive Leadership
Chunsheng Leng
Chairman of the Board, General Manager
Junye Wang
Chief Accounting Officer, Secretary of the Board, Director
Hong Chen
Deputy General Manager, Chief Engineer
Fengqin Li
Director
Yaren An
Independent Director
Price To Earnings (TTM) | 42.26 |
|---|---|
Price To Sales (TTM) | 13.21 |
Price To Book (MRQ) | 7.26 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 11.34 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | 17.29 |
Return on Equity (TTM) | 15.01 |
* Says it was recognized as high-tech enterprise and will enjoy a tax preference of 15 percent for three years
* Says it terminates former agreement with Harmony Biopharm Ltd and a Shanghai-based biomedicine firm, and signed a new one with Dance Biopharm Holding Inc and the Shanghai-based biomedicine firm, to set up a new biomedicine JV with registered capital of 102.6 million yuan
* Says H1 net profit up 30.2 percent y/y at 410.4 million yuan ($61.10 million)
Tonghua Dongbao Pharmaceutical Co Ltd * Says board elects Li Yikui as chairman Source text in Chinese: http://bit.ly/2qS0pX9 Further company coverage: (Reporting by Hong Kong newsroom)
* Says Q1 net profit up 30.2 percent y/y at 210.3 million yuan ($30.52 million)
Tonghua Dongbao Pharmaceutical Co Ltd * Says its shares to resume trade on March 30 Source text in Chinese: http://bit.ly/2ob10FV Further company coverage: (Reporting by Hong Kong newsroom)
* Says 9-month net profit up 28.6 percent y/y at 500.5 million yuan ($73.84 million)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.